TCN 032

Drug Profile

TCN 032

Alternative Names: Anti-influenza monoclonal antibody - Theraclone Sciences; IgG monoclonal antibody - Theraclone Sciences; TCN-032

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator Theraclone Sciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Influenza A virus M2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza A virus infections

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 03 Aug 2015 Phase II development is ongoing in United Kingdom, and phase I development is ongoing in USA
  • 10 Sep 2013 TCN 032 is available for licensing in World (excluding Japan) - www.theraclone-sciences.com
  • 09 Sep 2013 Efficacy data from a phase IIa trial in Influenza A virus infections (viral challenge in volunteers) released by Theraclone Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top